Study of Abatacept Versus Placebo to Assess the Prevention of Rheumatoid Arthritis (RA) in Adult Patients
Status:
Completed
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess if Abatacept given for six months will prevent
rheumatoid arthritis (RA) in patients who are at risk for the development of RA in comparison
to placebo. High risk patients are defined as those having a positive laboratory test for
anti-cyclic citrullinated peptide (anti-CCP2).